摘要
目的:评价咪唑斯汀治疗原发性获得性寒冷性荨麻疹的疗效与安全性。方法:采用多中心、随机双盲、安慰剂平行对照的方法,将入选患者随机分为试验组和对照组,分别接受咪唑斯汀和安慰剂治疗,观察患者对冷刺激试验的风团反应和瘙痒程度,以及临床反应。结果:试验组患者冷刺激试验的风团反应、冷刺激试验复温20min时的瘙痒程度、遇冷空气或冷水后出现风团或瘙痒的程度与安慰剂组相比有统计学差异(P<0.05)。结论:咪唑斯汀治疗原发性获得性寒冷性荨麻疹安全、有效。
Objective： The aim of this study is to evaluate the efficacy and safety of mizolastine, an antihistaminic with antiallergic properties in primary acquired cold urticaria（PACU）. Methods： The patients were randomly divided into two groups who received either mizolastine 10 mg/day or placebo for 14 days. Evaluating the wheal response of the cold stimulation test （CST） and measuring the patient-rated severity of itching. Results： The scores of the wheal response of the cold stimulation test and the patient-rated severity of itching after the cold stimulation test, the percents of patients having wheals or itching after being exposed into cold air or cold water in the mizolastine group were decreased as compared with those in placebo group（P〈0.05）. Conclusion： The results suggest that mizolastine may be effective and safe in the treatment of primary acquired cold urticaria.
出处
《临床皮肤科杂志》
CAS
CSCD
北大核心
2005年第10期697-699,共3页
Journal of Clinical Dermatology
